Relationship between mutations of epidermal growth factor receptor in the plasma and pleural effusion and responses to gefitinib in advanced pretreated non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 10, Issue 6, 2007, Pages 504-507

  Guo, Jian ^a   Zhou, Caicun ^a   Zhang, Jie ^a   Tang, Liang ^a  

^a SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Epidermal growth factor receptor; LightCycle PCR; Lung neoplasms; Mutation; Plasma; Pleural effusion

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ADVANCED CANCER; ARTICLE; CHI SQUARE TEST; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA ISOLATION; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TREATMENT RESPONSE; WILD TYPE;

EID: 38349039300     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest,2003,123(6):2096-2103;
2. Comment in: Chest,2004,125(5):1966-1967.
3. Meyerson M, Franklin WA, Kelley MJ. Molecular classification and molecular genetics of human lung cancers. Semin Oncol,2004,31(1 Suppl 1):4-19.
4. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res,2004,10(12 Pt 2):4227s-4232s.
5. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res,2002,62(20):5749-5754.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [Corrected]. J Clin Oncol,2003,21(12):2237-2246; Erratum in: J Clin Oncol,2004,22(23):4811;
7. Comment in: J Clin Oncol,2003,21(12):2227-2229; 2005,23(4):921-922.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16):2149-2158;
9. Comment in: JAMA,2004,291(13):1563-1564.
10. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer,2004,44(2):221-230.
11. Li LY, Zhou CC, Zhang GC. The value of EGFR mutation and gene amplification in predicting response to gefitinib in NSCLC patients. J Evid-Based Med,2006,6(1):23-27.
12. Pao W, Wang TY, Rell YGJ, et al. K-RAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlotinib. PLoS Med,2005,2(1):57-61.
13. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther,2004,6(3):273-278.
14. Stroun M, Lyautey J, Lederrey G, et al. About the possible origin and mechanism of circulating DNA: apoptosis and active DNA release. Clin Chim Acta,2001,313(1-2):139-142.
15. Zhou CC, Zhao YM, Tang L, et al. Epidermal growth factor receptor mutations in Chinese patients with non-small cell lung cancer. Tumor,2005,25(5):458-461.